Ovarialkarzinom bei der alten und geriatrischen Patientin

  • Frederik Marmé
  • Felix Hilpert
  • Dominik Denschlag
Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

In Deutschland erkranken jährlich etwa 7500 Frauen an einem Ovarialkarzinom, meist in fortgeschrittenem Stadium mit schlechter Prognose. Gut die Hälfe davon sind über 65 Jahre alt. Aufgrund der demografischen Entwicklung stellen sie die am stärksten wachsende Population dar. Eine optimale Primärtherapie mit oft multiviszeraler Operation und postoperativer Chemotherapie verbessert die Prognose deutlich. Ob bei älteren, komorbiden Patientinnen dieser aggressive Standard ebenso sinnvoll ist, oder ggf. mehr schadet, ist unklar. Von daher werden ältere Patientinnen mit Ovarialkarzinom häufig weniger aggressiv behandelt. Aber auch die seltenere Leitlinien-getreue Therapie kann zu einer schlechteren Prognose mit bis zu 2-fach höherer Mortalität beitragen. Der Grat zwischen Unter- und Übertherapie ist schmal und verlässliche, für das Ovarialkarzinom spezifische prädiktive Scores, die eine Individualisierung ermöglichen, gibt es nicht. Prospektive Studien hierzu laufen aktuell in Deutschland.

Literatur

  1. Aletti GD, Eisenhauer EL, Santillan A, Axtell A, Aletti G, Holschneider C, Chi DS, Bristow RE, Cliby WA (2011) Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol 120:23–28CrossRefPubMedGoogle Scholar
  2. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483CrossRefPubMedGoogle Scholar
  3. Chow WB, Rosenthal RA, Merkow RP, Ko CY, Esnaola NF, American College of Surgeons National Surgical Quality Improvement P, American Geriatrics S (2012) Optimal preoperative assessment of the geriatric surgical patient: a best practices guideline from the American College of Surgeons National Surgical Quality Improvement Program and the American Geriatrics Society. J Am Coll Surg 215:453–466CrossRefPubMedGoogle Scholar
  4. Cornelis S, Van Calster B, Amant F, Leunen K, van der Zee AG, Vergote I (2012) Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological Oncology. Int J Gynecol Cancer 22:407–416CrossRefPubMedGoogle Scholar
  5. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115:1234–1244CrossRefPubMedGoogle Scholar
  6. Fader AN, von Gruenigen V, Gibbons H, Abushahin F, Starks D, Markman M, Belinson J, Rose P (2008) Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol 109:33–38CrossRefPubMedGoogle Scholar
  7. Falandry C, Weber B, Savoye AM, Tinquaut F, Tredan O, Sevin E, Stefani L, Savinelli F, Atlassi M, Salvat J, Pujade-Lauraine E, Freyer G (2013) Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. Ann Oncol 24:2808–2813CrossRefPubMedGoogle Scholar
  8. Freyer G, Geay JF, Touzet S, Provencal J, Weber B, Jacquin JP, Ganem G, Tubiana-Mathieu N, Gisserot O, Pujade-Lauraine E (2005) Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 16:1795–1800CrossRefPubMedGoogle Scholar
  9. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health Study Collaborative Research G (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–M156CrossRefPubMedGoogle Scholar
  10. Gondos A, Holleczek B, Arndt V, Stegmaier C, Ziegler H, Brenner H (2007) Trends in population-based cancer survival in Germany: to what extent does progress reach older patients? Ann Oncol 18:1253–1259CrossRefPubMedGoogle Scholar
  11. Hilpert F, Hempel AM, Hedderich J, Junge O, Harter P, Bois AD, Pfisterer J (2011) Age-specific prognostic factors for survival in patients with advanced ovarian cancer (OC) treated with platinum/taxane-based primary chemotherapy: a combined explorative analysis of three prospective phase III trials from the AGO study group. J Clin Oncol 29:5057–5057CrossRefGoogle Scholar
  12. Hilpert F, Wimberger P, du Bois A, Pfisterer J, Harter P (2012) Treatment of elderly ovarian cancer patients in the context of controlled clinical trials: a joint analysis of the AGO Germany experience. Onkologie 35:76–81CrossRefPubMedGoogle Scholar
  13. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29:3457–3465CrossRefPubMedPubMedCentralGoogle Scholar
  14. Janda M, Youlden DR, Baade PD, Jackson D, Obermair A (2008) Elderly patients with stage III or IV ovarian cancer: should they receive standard care? Int J Gynecol Cancer 18:896–907CrossRefPubMedGoogle Scholar
  15. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386:249–257CrossRefPubMedGoogle Scholar
  16. Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ, Participants in the VANSQIP (2005) Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg 242:326–341; discussion 341–343PubMedPubMedCentralGoogle Scholar
  17. Korc-Grodzicki B, Downey RJ, Shahrokni A, Kingham TP, Patel SG, Audisio RA (2014) Surgical considerations in older adults with cancer. J Clin Oncol 32:2647–2653CrossRefPubMedGoogle Scholar
  18. Lin JJ, Egorova N, Franco R, Prasad-Hayes M, Bickell NA (2016) Ovarian cancer treatment and survival trends among women older than 65 years of age in the United States, 1995–2008. Obstet Gynecol 127:81–89CrossRefPubMedPubMedCentralGoogle Scholar
  19. Maas HA, Kruitwagen RF, Lemmens VE, Goey SH, Janssen-Heijnen ML (2005) The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol 97:104–109CrossRefPubMedGoogle Scholar
  20. Makary MA, Segev DL, Pronovost PJ, Syin D, Bandeen-Roche K, Patel P, Takenaga R, Devgan L, Holzmueller CG, Tian J, Fried LP (2010) Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg 210:901–908CrossRefPubMedGoogle Scholar
  21. O'Malley CD, Shema SJ, Cress RD, Bauer K, Kahn AR, Schymura MJ, Wike JM, Stewart SL (2012) The implications of age and comorbidity on survival following epithelial ovarian cancer: summary and results from a Centers for Disease Control and Prevention study. J Womens Health (Larchmt) 21:887–894CrossRefGoogle Scholar
  22. Parmar MKB, Adams M, Balestrino M, Bertelsen K, Bonazzi C, Calvert H, Colombo N, Delaloye JF, Durando A, Guthrie D, Hagen B, Harper P, Mangioni C, Perren T, Poole C, Qian W, Rustin G, Sandercock J, Tumolo S, Torri V et al (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360:505–515CrossRefGoogle Scholar
  23. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stahle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496CrossRefPubMedGoogle Scholar
  24. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C et al (2014) Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15:396–405CrossRefPubMedGoogle Scholar
  25. Pope D, Ramesh H, Gennari R, Corsini G, Maffezzini M, Hoekstra HJ, Mobarak D, Sunouchi K, Stotter A, West C, Audisio RA (2006) Pre-operative assessment of cancer in the elderly (PACE): a comprehensive assessment of underlying characteristics of elderly cancer patients prior to elective surgery. Surg Oncol 15:189–197CrossRefPubMedGoogle Scholar
  26. Robinson TN, Eiseman B, Wallace JI, Church SD, McFann KK, Pfister SM, Sharp TJ, Moss M (2009) Redefining geriatric preoperative assessment using frailty, disability and co-morbidity. Ann Surg 250:449–455PubMedGoogle Scholar
  27. Robinson TN, Wallace JI, Wu DS, Wiktor A, Pointer LF, Pfister SM, Sharp TJ, Buckley MJ, Moss M (2011) Accumulated frailty characteristics predict postoperative discharge institutionalization in the geriatric patient. J Am Coll Surg 213:37–42; discussion 42–44CrossRefPubMedPubMedCentralGoogle Scholar
  28. Saliba D, Elliott M, Rubenstein LZ, Solomon DH, Young RT, Kamberg CJ, Roth C, MacLean CH, Shekelle PG, Sloss EM, Wenger NS (2001) The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 49:1691–1699CrossRefPubMedGoogle Scholar
  29. Satariano WA, Ragland DR (1994) The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104–110CrossRefPubMedGoogle Scholar
  30. Sperling C, Noer MC, Christensen IJ, Nielsen ML, Lidegaard O, Hogdall C (2013) Comorbidity is an independent prognostic factor for the survival of ovarian cancer: a Danish register-based cohort study from a clinical database. Gynecol Oncol 129:97–102CrossRefPubMedGoogle Scholar
  31. Tew WP, Fleming GF (2015) Treatment of ovarian cancer in the older woman. Gynecol Oncol 136:136–142CrossRefPubMedGoogle Scholar
  32. Tew WP, Muss HB, Kimmick GG, Von Gruenigen VE, Lichtman SM (2014) Breast and ovarian cancer in the older woman. J Clin Oncol 32:2553–2561CrossRefPubMedGoogle Scholar
  33. Thrall MM, Goff BA, Symons RG, Flum DR, Gray HJ (2011) Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol 118:537–547CrossRefPubMedPubMedCentralGoogle Scholar
  34. Tredan O, Geay JF, Touzet S, Delva R, Weber B, Cretin J, Provencal J, Martin J, Stefani L, Pujade-Lauraine E, Freyer G, Groupe d’Investigateurs Nationaux pour l'Etude des Cancers O (2007) Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l’Etude des Cancers Ovariens. Ann Oncol 18:256–262CrossRefPubMedGoogle Scholar
  35. van Meurs HS, Tajik P, Hof MH, Vergote I, Kenter GG, Mol BW, Buist MR, Bossuyt PM (2013) Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur J Cancer 49:3191–3201CrossRefPubMedGoogle Scholar
  36. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943–953CrossRefPubMedGoogle Scholar
  37. Wright JD, Lewin SN, Deutsch I, Burke WM, Sun X, Neugut AI, Herzog TJ, Hershman DL (2011) Defining the limits of radical cytoreductive surgery for ovarian cancer. Gynecol Oncol 123:467–473CrossRefPubMedGoogle Scholar
  38. Wright JD, Herzog TJ, Neugut AI, Burke WM, Lu YS, Lewin SN, Hershman DL (2012) Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. Obstet Gynecol 120:871–881CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Frederik Marmé
    • 1
  • Felix Hilpert
    • 2
  • Dominik Denschlag
    • 3
  1. 1.Translationale Gynäkologische OnkologieUniversitätsfrauenklinik und Nationales Centrum für Tumorerkrankungen (NCT) HeidelbergHeidelbergDeutschland
  2. 2.Onkologisches Therapiezentrum HamburgKrankenhaus JerusalemHamburgDeutschland
  3. 3.Brust- und Gynäkologisches Krebszentrum (DKG)Hochtaunuskliniken Bad HomburgBad HomburgDeutschland

Section editors and affiliations

  • Nicolai Härtel
    • 1
  1. 1.Interdisziplinäres TumorzentrumUniversitätsmedizin MannheimMannheimDeutschland

Personalised recommendations